Team

Roland Kozlowski BSc (Hons), PhD

Executive Chairman

Roland is a Mentor, Investor and Company Director involved in a number of emerging biotech companies with a great understanding of the Polish Life Science Eco-System from the perspective of a Western practitioner. He also holds the position of Chief Commercial Officer at the Malopolskie Centre of Biotechnology in Krakow.

He received a first class honors degree from the University of Bath and a PhD from the University of Cambridge. He has now worked in the industry for approaching thirty years and was Chief Executive Officer of Lectus Therapeutics and Sense Proteomic Limited, two UK based venture capital backed companies which he co-founded, built and sold. Earlier in his career Roland ran Research Groups at the University of Oxford and University of Bristol where he published and patented in the life sciences. He has served on, or advised the boards of several European companies, VC funds and charitable organizations. In Poland he co-founded, and was until recently, a limited partner in Life Science Innovations a VC fund specializing in life-science investment.

Roland has acted as an advisor to the National Centre of Research & Development and the Polish Development Agency predominantly though a specialist consultancy boutique he created called Life Science Biznes Consulting LSBC Sp. z o.o.

Stefan Ogrodzinski

Stefan Ogrodzinski BSc (Hons), MBA

Chief Executive Officer

Stefan Ogrodzinski received his BSc (Hons) in Toxicology and Pharmacology from The School of Pharmacy, University College London, in 1987 and his MBA from De Montfort University in 1999.

Stefan's career has spanned the pharmaceutical industry, the healthcare sector, the voluntary sector and the educational sector, giving 30 years of sales, marketing, management and directorship experience.

In 2000, Stefan founded BioStatus and since that time has led the company as its CEO. OncoTherics was spun out of BioStatus in 2012. As a founding Director of OncoTherics, Stefan is responsible for the early stage fundraising, direction and strategic management of the business. He is also the President of the newly formed, wholly owned Polish subsidiary company, OncoTherics Poland Sp. zo. o.

Stefan has also been centrally involved in the development of a number of successful life science companies in the UK, including MedilinkEM, BioCity Group, MediCity and Mobius Technology Ventures (BioCity's Life Sciences Investment Fund). He is currently an active Director of BioSuspensions and BioTherics and sits on the advisory panel for the Centre for Doctoral Training in Targeted Therapeutics and Formulation Science at Nottingham University.

Kinga Drechny-Mucha

Pełnomocnik Zarządu i Dyrektor Marketingu i Komunikacji

Thomas Morris

Dr Thomas Morris BSC, MB BCh, MRCP, FFPM, LlM

Chief Medical Officer

Dr Thomas Morris received his BSc in Physiology from the University of Wales in 1984, his medical degrees in 1987 from the University of Wales College of Medicine, and his Master of Laws degree from Cardiff Law School in 2009.

Thomas has worked in drug development for over 20 years with much of this time specialising in oncology. After deciding to specialise in pharmaceutical medicine, he worked first for Medeval Ltd (University of Manchester) and latterly AstraZeneca, where he has held a number of senior global R&D roles. Most recently these include Senior Medical Director, Executive Director Clinical Programs and Medical Science Director. He has overseen the clinical development of several global drug programs, interacting with academic groups and regulatory agencies worldwide and brings a wealth of experience in Clinical Trial Management to OncoTherics.

Thomas is a Fellow and Board member of The Faculty of Pharmaceutical Medicine, a former chair of its Ethical Issues committee and a member of its Professional Standards Committee.

Paul Smith

Professor Paul Smith BSc, PhD

Chief Scientific Officer

Professor Paul J Smith received his BSc in Medical Microbiology from the University of Bristol in 1974, and received his PhD in 1977 from the University of Manchester for studies on cellular radiobiology at the Paterson Institute, Manchester. He has been active in the field of cellular responses to DNA damage for over 20 years.

Between 1977 and 1979 he was a NERC (Canada) Research Fellow in the Biology Branch of Chalk River Nuclear Laboratories (CRNL) Canada and later as a research scientist funded by the US National Cancer Institute investigating DNA repair in persons genetically predisposed to cancer. In 1982 he joined the Medical Research Council Centre (Cambridge, UK) and as a senior scientist led a programme directed towards the identification of factors controlling cellular sensitivity to DNA damage. In 1995 he was appointed to the new Chair of Cancer Biology at the University of Wales College of Medicine. He is also a past President of the International Society for Analytical Cytology (ISAC).

In addition Paul is extremely well known on the International research circuit, and is highly respected by key opinion leaders all over the world.

Laurence Patterson

Professor Laurence Patterson BSc (Hons), PhD

Chief Operating Officer

Professor Laurence Patterson obtained his BSc (hons) in applied biology from the University of Hertfordshire and his PhD in the area of medicinal chemistry from King's College, London. He subsequently spent several years in the pharmaceutical industry before taking up a post at De Montfort University, Leicester where he progressed to Prof of Pharmaceutical biochemistry and then on to Professor of medicinal chemistry and Head of the Department of Pharmaceutical and Biological Chemistry at The School of Pharmacy, University College London. Laurence is responsible for the discovery of AQ4N.

Currently, Laurence is a research Professor and former Director of the Institute of Cancer Therapeutics (ICT), University of Bradford. The ICT builds on 30 years of highly successful cancer pharmacology research in Bradford which, under Laurence's leadership has advanced new medicines discovery in the UK.

Laurence brings a good deal of technical and commercial expertise to the team along with a vast International network of contacts in the company's key market areas. He is able to offer expert advice and technical support.

Justyna Supel

Dyrektor Operacyjny Polska

Stephanie McKeown

Professor Stephanie McKeown BA (Oxon), PhD, CBiol MIBiol

Project Director

Professor McKeown graduated in 1973 from Oxford University with a BA (Natural Sciences, Biochemistry). Her PhD on the pathogenesis of multiple sclerosis (MS) was completed at Queens University Belfast. She joined the University of Ulster in 1991 as a lecturer, promoted to a Chair in Cancer Biology in 2002. In 2010 she was appointed as Director of the Health and Rehabilitation Science Research Institute.

Stephanie's main research interests are focused around tumour radiobiology with particular reference to hypoxia and the role of the tumour microvasculature in treatment response. The work of her laboratory provided the majority of the data for the preclinical development of AQ4N. During this process she was a member of the clinical trials advisory committee funded jointly by Cancer Research Campaign and an industrial partner.

Mike Leyland

Mike Leyland BSc, FCA

Chief Finance Officer

Michael Leyland is a widely experienced, senior finance executive specialising in guiding early biotech start-up companies.

Mike graduated from Kings College London with a degree in Chemistry, before taking an assistant manager's position at Thomson Mclintock & Co (now KPMG). After qualifying as an accountant with the Institute of Chartered Accountants, he moved to British Leyland to take up a position as Financial Accounting Manager. He then moved to Glaxo where he worked for 16 years in a variety of senior positions including FD for Glaxo Export Ltd, FD Glaxo Companies Singapore, Group Deputy Treasurer and Director of Administration Glaxo Wellcome plc (Geneva).

In the last 10 years, Mike has served as the Director of European operations for A. M. Pappas & Associates.

Mike brings a wealth of expertise to OncoTherics, both as an executive and non-executive director of OFEX and other private companies and major subsidiaries of Glaxo world-wide. He is a valuable member of the OncoTherics team offering financial and strategic support to the company.

Roy Eady

Roy Eady BSc PhD

Rada Nadzorca

After qualifying with a first degree in Physiology & Chemistry from the University of London in 1968 and a PhD London (Physiology) from Bedford College, University of London in 1972, (Membrane Proteins from Human Erythrocytes as Possible ÇCarriers for the Hexose Transport System), Roy has built extensive, top-level, leadership and management experience of the Drug Discovery (Fisons Pharmaceuticals) and Drug Development (Astra & AstraZeneca) processes.

Roy is a multi-talented scientist with specialist pharma consulting competencies. Latterly he has been involved in business development projects in private and public funded companies, leading a number of global of change management processes including Global Project Team organisation, Project and Portfolio Management.

Roy brings a wealth of pharmaceutical and project management experience to the OncoTherics board.

Bob Humphries

Bob Humphries BSc (Hons)

Rada Nadzorca

Bob gained his BSc (Hons) in Pharmacology from the University of Bradford in 1979. His subsequent 32 year career in the Pharmaceutical industry has been with Fisons, Astra then AstraZeneca as a pharmacologist, scientific team leader and cross functional project team leader.

Bob led the discovery project teams responsible for the discovery and early progression of the anti-thrombotic (P2Y12 antagonists) compounds BRILINTA and cangrelor - medicines that have, and will, save patients' lives. He is a Recipient of a 2010 CEO's award for leading the BRILINTA Discovery Project and also featured in R&D Directions Most Notable People in R&D in 2009 for the BRILINTA story

Since leaving AstraZeneca in April 2012, Bob has been working with clients to develop strategies, target profiles and development plans for respiratory, inflammation, oncology and scar prevention projects. He brings a welcome breadth of experience to the OncoTherics board.